阿帕替尼联合依托泊苷软胶囊治疗晚期铂耐药卵巢癌的疗效观察

Clinical observation of Apatinib combined with etoposide soft capsules in the treatment of advanced platinum-resistant ovarian cancer

目的探讨阿帕替尼联合依托泊苷软胶囊治疗晚期铂耐药卵巢癌的疗效。方法选取30例晚期铂耐药卵巢癌患者,根据随机抽样法将患者分成常规组与研究组,每组15例。常规组患者使用阿帕替尼单独治疗,研究组患者使用阿帕替尼联合依托泊苷软胶囊治疗。对比两组患者的治疗效果,包括客观缓解率(ORR)、疾病控制率(DCR)、不良反应发生情况及生活质量。结果研究组ORR、DCR分别为60.00%、86.67%,均高于常规组的20.00%、46.67%(P<0.05)。研究组生理、心理、环境、社会关系评分均高于常规组(P<0.05)。研究组不良反应发生率略高于常规组,但比较差异无统计学意义(P>0.05)。结论晚期铂耐药卵巢癌患者使用阿帕替尼联合依托泊苷软胶囊进行治疗,可以改善患者生活质量,提高患者治疗效果,临床应用价值较高。

Objective To investigate the efficacy of Apatinib combined with etoposide soft capsules in the treatment of advanced platinum-resistant ovarian cancer.Methods 30 patients with advanced platinum-resistant ovarian cancer were selected and randomly divided into conventional group and research group,with 15 patients in each group.The conventional group was treated with Apatinib alone,while the study group was treated with Apatinib combined with etoposide soft capsules.The therapeutic effects of the two groups were compared,including objective response rate(ORR),disease control rate(DCR),occurrence of adverse reactions and quality of life.Results The ORR and DCR of the study group were 60.00%and 86.67%,respectively,which were higher than those of the conventional group(20.00%and 46.67%,P<0.05).The scores of physiological,psychological,environmental and social relations in the study group were higher than those in the conventional group(P<0.05).The incidence of adverse reactions in the study group was slightly higher than that in the conventional group,but there was no statistical significance(P>0.05).Conclusion Apatinib combined with etoposide soft capsules for treatment of advanced platinum-resistant ovarian cancer patients can improve the quality of life of patients,improve the therapeutic effect of patients,and have high clinical application value.